Cabozantinib-based combination therapy for the treatment of hepatocellular carcinoma

OBJECTIVE: Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer with limited treatment options. Cabozantinib, an orally bioavailable multikinase inhibitor is now approved by Food and Drug Administration (FDA) for HCC patients. We evaluated the therapeutic efficacy of caboza...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Gut
Main Authors: Shang, Runze, Song, Xinhua, Wang, Pan, Zhou, Yi, Lu, Xinjun, Wang, Jingxiao, Xu, Meng, Chen, Xinyan, Utpatel, Kirsten, Che, Li, Liang, Binyong, Cigliano, Antonio, Evert, Matthias, Calvisi, Diego F, Chen, Xin
Formato: Artigo
Idioma:Inglês
Publicado em: BMJ Publishing Group 2021
Assuntos:
Hepatology
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8089119/
https://ncbi.nlm.nih.gov/pubmed/33144318
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/gutjnl-2020-320716
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados